![]() | Thomas Anton Luger |
Prominent publications by Thomas Anton Luger
BACKGROUND: Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We report the 60-week data from the UNCOVER-2 and UNCOVER-3 trials, as well as 12-week and 60-week data from a third phase 3 trial, UNCOVER-1.
METHODS: We randomly assigned 1296 patients in the UNCOVER-1 trial, 1224 patients in the UNCOVER-2 trial, ...
Also Ranks for: 3 Trials | ixekizumab placebo | week patients | spga score | starting dose |
Intercellular adhesion molecule-1 (ICAM-1) is involved in cell-cell interactions of leukocytes and parenchymal cells and thus plays an important role in immunologic and inflammatory reactions. The expression of ICAM-1 that is found on many different cells such as melanocytes and melanoma cells is induced by various cytokines, including interferon-gamma (IFN gamma), interleukin (IL)-1 and tumor necrosis factor alpha (TNF alpha). Because expression of ICAM-1 in melanoma was found to ...
Also Ranks for: Melanoma Cells | intercellular adhesion | icam1 expression | tnf alpha | human melanocytes |
Irradiation with ultraviolet (UV) B radiation results in the formation of apoptotic keratinocytes called sunburn cells. Recently, it was demonstrated that keratinocytes can release tumor necrosis factor-alpha (TNF-alpha), which is known to cause apoptosis in particular cells. In addition, it has been shown that UVB light induces the release of TNF-alpha by keratinocytes and that keratinocytes express the 55-kD receptor for TNF-alpha. Therefore, we investigated whether TNF-alpha is ...
Also Ranks for: Sunburn Cells | induced apoptosis | tumor necrosis | tnfalpha keratinocytes | alpha tnf |
BACKGROUND: In previous studies, etanercept 25 mg twice weekly (BIW) or 50 mg BIW significantly reduced disease severity in patients with plaque psoriasis and demonstrated a favourable safety profile.
OBJECTIVES: To assess the efficacy and safety of etanercept 50 mg administered once weekly (QW) compared with placebo in patients with moderate-to-severe plaque psoriasis over 24 weeks.
METHODS: This study was conducted in two parts: (i) a 12-week, double-blind, placebo-controlled phase, in ...
Also Ranks for: Etanercept 50 | plaque psoriasis | week patients | placebo qw | baseline pasi |
BACKGROUND: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has been shown to have significant efficacy and a favourable safety profile in the treatment of moderate-to-severe psoriasis and psoriatic arthritis.
OBJECTIVE: To assess the efficacy and safety of secukinumab through 5 years of treatment in moderate-to-severe psoriasis.
METHODS: In the core SCULPTURE study, Psoriasis Area and Severity Index (PASI) 75 responders at Week 12 continued receiving ...
Also Ranks for: 5 Years | extension study | monoclonal antibodies | favourable safety | sustained efficacy |
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.
OBJECTIVES: To determine the 16-week efficacy and safety of two oral tofacitinib doses vs. placebo in patients with moderate-to-severe chronic plaque psoriasis.
METHODS: Patients in two similarly designed phase III studies (OPT Pivotal 1, NCT01276639, n = 901; OPT Pivotal 2, NCT01309737, n = 960) were initially randomized 2 : 2 : 1 to tofacitinib 10 or 5 mg or placebo, twice daily. Coprimary ...
Also Ranks for: Tofacitinib Placebo | opt pivotal | plaque psoriasis | phase iii | oral janus |
Corticotropin Releasing Hormone and Proopiomelanocortin Involvement in the Cutaneous Response to Stress
[ PUBLICATION ]
The skin is a known target organ for the proopiomelanocortin (POMC)-derived neuropeptides alpha-melanocyte stimulating hormone (alpha-MSH), beta-endorphin, and ACTH and also a source of these peptides. Skin expression levels of the POMC gene and POMC/corticotropin releasing hormone (CRH) peptides are not static but are determined by such factors as the physiological changes associated with hair cycle (highest in anagen phase), ultraviolet radiation (UVR) exposure, immune cytokine ...
Also Ranks for: Corticotropin Releasing | pomc peptides | cutaneous response | skin expression | hormone receptors |
Ultraviolet Light Induces Apoptosis via Direct Activation of CD95 (Fas/APO-1) Independently of Its Ligand CD95L
[ PUBLICATION ]
Induction of apoptosis in keratinocytes by UV light is a critical event in photocarcinogenesis. Although p53 is of importance in this process, evidence exists that other pathways play a role as well. Therefore, we studied whether the apoptosis-related surface molecule CD95 (Fas/APO-1) is involved. The human keratinocyte cell line HaCaT expresses CD95 and undergoes apoptosis after treatment with UV light or with the ligand of CD95 (CD95L). Incubation with a neutralizing CD95 antibody ...
Also Ranks for: Uv Light | direct activation | ligand cd95 | induces apoptosis | recruitment fadd |
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a new member of the tumor necrosis factor (TNF) family, induces apoptosis primarily of transformed cells. Interleukin-1 was previously found to protect the keratinocyte cell line KB from TRAIL-induced apoptosis, thus we studied whether interleukin-1 also protects from other apoptotic stimuli (ultraviolet radiation (UV), CD95-ligand). Interleukin-1 rescued KB cells from TRAIL- and CD95-induced apoptosis, which was critically ...
Also Ranks for: Tumor Necrosis | induced apoptosis | ultraviolet radiation | transformed keratinocytes | inducing ligand |
BACKGROUND: Since the publication of the European League Against Rheumatism recommendations for the pharmacological treatment of psoriatic arthritis (PsA) in 2012, new evidence and new therapeutic agents have emerged. The objective was to update these recommendations.
METHODS: A systematic literature review was performed regarding pharmacological treatment in PsA. Subsequently, recommendations were formulated based on the evidence and the expert opinion of the 34 Task Force members. ...
Also Ranks for: European League | pharmacological therapies | psoriatic arthritis | recommendations evidence | overarching principles |
Proteinase-activated receptor 2 belongs to a new G protein-coupled receptor subfamily activated by various serine proteases. It has been demonstrated to play a role during inflammation of many tissues including the skin. Proteinase-activated receptor 2 is expressed by endothelial cells and regulates cutaneous inflammation in vivo. The underlying mechanisms of proteinase-activated receptor 2 activation in the skin and the effects on human dermal microvascular endothelial cells, however, ...
Also Ranks for: Endothelial Cells | activated receptor | cutaneous inflammation | inflammatory responses | human dermal |
OBJECTIVE: Recently, we found that human dermal fibroblasts (HDFs) express melanocortin 1 receptors (MC-1R) that bind alpha-melanocyte-stimulating hormone (alpha-MSH). In search of novel therapies for scleroderma (systemic sclerosis [SSc]), we used the bleomycin (BLM) model to investigate the effects of alpha-MSH on collagen synthesis and fibrosis.
METHODS: Collagen expression in HDFs was determined by real-time reverse transcription-polymerase chain reaction (RT-PCR) and Western blot ...
Also Ranks for: Mouse Model | tissue fibrosis | melanocortin peptides | stimulating hormone | messenger receptors |
Pentoxifylline (PTX) is a methylxanthine compound known to inhibit the production of tumour necrosis factor-alpha (TNF-alpha), which is an important inflammatory mediator. There is also recent evidence that PTX may influence other inflammatory cytokines, such as interleukin-1 (IL-1) and IL-6. Due to the therapeutic implications, the present study addressed the in vivo effects of PTX on the release of TNF-alpha, IL-1 beta, IL-6 and IL-8 by human peripheral blood mononuclear cells (PBMC). ...
Also Ranks for: Necrosis Factor | mononuclear cells | pentoxifylline ptx | cytokine release | il1 beta |
Thomas Anton Luger: Influence Statistics
Concept | World rank |
---|---|
german society dermatology | #1 |
development sunscreens | #1 |
hrqol joint pain | #1 |
granulocytes ecgram | #1 |
ace acth msh | #1 |
german inpatient dermatology | #1 |
alphamsh animal models | #1 |
systemic administration tacrolimus | #1 |
cd95 uv | #1 |
dermatologic subspecialties | #1 |
cle hcs | #1 |
patients itch reduction | #1 |
express prohormone convertases | #1 |
melanocortin peroxidase receptor | #1 |
cytokines epidermal | #1 |
localization3377 | #1 |
kpv treatment | #1 |
eccontra | #1 |
antiinflammatory effects role | #1 |
betaendorphin vesicular structures | #1 |
tnf alpha formation | #1 |
mice ndpmsh | #1 |
immune skin cells | #1 |
irradiated cells restoration | #1 |
impact ixekizumab treatment | #1 |
variety immunomodulating activities | #1 |
thymocytes transcriptional activation | #1 |
addition uv light | #1 |
receptors skin diseases | #1 |
pruritus pain pathogenesis | #1 |
mc1r dss colitis | #1 |
peroxidase receptor | #1 |
intravenous skin | #1 |
pruritus 2 phase | #1 |
systemic autoimmunity induction | #1 |
ecgram enhanced response | #1 |
18 patients azathioprine | #1 |
cytokines hmec1 | #1 |
melanocortin analogue patients | #1 |
melanocortin1 receptor cells | #1 |
safest options | #1 |
il3 activity etaf | #1 |
dhavd neurokinin1 receptor | #1 |
uvb light apoptosis | #1 |
apcs alphamsh | #1 |
partial iga deficiency | #1 |
monocytes keratinocytes | #1 |
ccle p005 | #1 |
promising compounds treatment | #1 |
crisaborole pruritus | #1 |
Open the FULL List in Excel | |
Key People For Atopic Dermatitis
Thomas Anton Luger:Expert Impact
Concepts for whichThomas Anton Lugerhas direct influence:Atopic dermatitis, Chronic pruritus, Pimecrolimus cream.
Thomas Anton Luger:KOL impact
Concepts related to the work of other authors for whichfor which Thomas Anton Luger has influence:Atopic dermatitis, Psoriatic arthritis, Mast cells, Human keratinocytes, Chronic pruritus, Necrosis factor, Gene expression.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |